[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"suicidal-ideation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:suicidal-ideation":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,105,0,25,[9,45,81,104,135,165,200,231,254,281,314,343,372,397,427,455,475,487,519,543,572,594,616,640,665],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100054164","a-randomized-controlled-trial-of-a-smartphone-delivered-treatment-for-suicidal-thoughts-and-behavior-100054164",false,"NCT06686901","A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior","Inclusion Criteria:\n\n* Adults ages 18+\n* Relatively frequent and recent (≥5 days within the past-month) active suicidal thoughts as assessed via SITBI-R.\n* Willing and able to provide at least one emergency contact (name, phone number, relation).\n* Owns an Android or iOS smartphone.\n* Possesses at least occasional access to Wi-Fi-enabled internet for data down\u002Fuploads.\n* Fluent in English and willing to provide informed consent.\n* Living in the Boston metropolitan area (i.e., \\~50 mile radius around Boston, MA)\n\nExclusion Criteria:\n\n* Recent (past 3-month) hypo\u002Fmanic symptoms or homicidal ideation or lifetime psychosis spectrum diagnosis as assessed via MINI 7.0.2.\n* Recent acute suicide risk operationalized as affirmative responses to BOTH below items during structured clinical interview AND evaluation by the PI in consultation with Mentors\u002FAdvisor Drs. Wilhelm, Kleiman, and\u002For Bentley:\n* At any time in past week: ≥ 8\u002F10 current intent to act on suicidal thoughts (0 \\[\"not at all\"\\] to 10 \\[\"extremely strong\"\\]); AND\n* At any time in past week: thought of a specific suicide plan (i.e, known method\u002Fmeans and\u002For location) with access to lethal means\n* Impaired vision (e.g., legal blindness), technological illiteracy, or intellectual disability that might impair ability to provide valid data and\u002For informed consent.","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate the acceptability, safety, and efficacy of a smartphone-delivered intervention called Therapeutic Evaluative Conditioning for Suicide (TEC-S) in reducing suicidal thoughts and behaviors (STB) among adults with recent and frequent suicide ideation.",[26,27],"Suicidal Ideation","Suicide Attempt",[29,30,31],"Suicide","ecological momentary assessment (EMA)","Therapeutic Evaluative Conditioning (TEC)","NOT_YET_RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":20},"2027-01-30",{"date":40,"type":20},"2029-08-31",{"name":42,"class":43},"Massachusetts General Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100054040","phase-2-inhaled-dmt-for-major-depressive-disorder-100054040","NCT07562191","Inhaled DMT for Major Depressive Disorder","Randomized, Double-Blind, Placebo-Controlled Phase IIb Trial of Inhaled N,N-Dimethyltryptamine (DMT) for Major Depressive Disorder","DMT-MDD","Inclusion Criteria:\n\n* 18 years or older, capable of making decisions, and able to provide informed consent.\n* Major Depressive Disorder (MDD) according to DSM-5 criteria\n* Current depressive episode of moderate to severe intensity\n* Episode duration of at least two weeks\n* Baseline MADRS score ≥ 20\n* No treatment changes (including antidepressants) in the 4 weeks prior to the study\n* Abstain from psychedelics ≥14 days before dosing (D0)\n\nExclusion criteria:\n\n* Major cardiac, hepatic, or renal disease; unstable cardiovascular conditions\n* Uncontrolled hypertension, QTc prolongation, arrhythmias, or valvular disease COPD or asthma\n* Severe obesity, uncontrolled diabetes, coagulopathy, thyroid disease, or glaucoma\n* Neurological risk (e.g., aneurysm, ↑ICP, epilepsy\u002Fseizures, severe disorders)\n* MAO deficiency or history of serotonin syndrome\n* Pregnant, breastfeeding, positive test, or no effective contraception\n* Secondary depression\n* Cluster B personality disorders (incl. borderline with ≥2 suicidal behaviors in past 12 months) or poor therapeutic rapport\n* Psychotic disorders, MDD with psychotic features, or first-degree family history of psychosis\u002Fbipolar disorder\n* Mania\u002Fhypomania\n* OCD, dissociative disorders, active PTSD, or decompensated eating disorders\n* Moderate-severe use disorder (past 6 months; except nicotine\u002Fcaffeine)\n* Lifetime ketamine, PCP, psychedelics, or MDMA use disorder\n* Current use of MAO inhibitors, unless discontinued at least 14 days prior to dosing\n* Psychedelic trial participation in past 12 months\n* Cognitive impairment affecting valid assessment",{"count":54,"type":20},140,[56],"PHASE2","This Phase 2b, randomized, double-blind, active-controlled clinical trial will evaluate the efficacy and safety of inhaled N,N-dimethyltryptamine (DMT) in adults with Major Depressive Disorder (MDD).\n\nThe study will test whether inhaled DMT can rapidly reduce depressive symptoms and suicide risk compared with a low-dose active comparator. A total of 140 participants will be randomized 1:1 to receive either 15 mg followed 1 hour later by 60 mg of inhaled DMT, or 1 mg followed 1 hour later by 4 mg of inhaled DMT.\n\nParticipants who do not achieve remission at Day 7 will enter an open-label extension and receive a high-dose DMT session on Day 14 (±3 days). All participants will be followed for up to 12 months to evaluate the durability of response, safety, functioning, and quality of life.",[59,60,61,26,29],"MDD","Major Depressive Disorder (MDD)","Major Depression",[63,64,65,66,67,68,69,70],"DMT","major depressive disorder","N,N-dimethyltryptamine","psychedelic therapy","inhaled DMT","vaporized DMT","suicidality","non invasive","RECRUITING","2026-07-09",{"date":35,"type":36},{"date":75,"type":20},"2026-08-01",{"date":77,"type":20},"2027-08-01",{"name":79,"class":43},"Universidade Federal do Rio Grande do Norte",5,{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":44},"100538044","enhancing-the-effectiveness-of-prolonged-exposure-among-suicidal-individuals-with-ptsd-100538044","NCT06285708","Enhancing the Effectiveness of Prolonged Exposure Among Suicidal Individuals With PTSD","Inclusion Criteria:\n\n* Current diagnosis of PTSD or subthreshold PTSD; ability to speak and understand the English language; and ability to complete the informed consent process.\n\nExclusion Criteria:\n\n* Substance use disorder requiring medical management; imminent suicide risk warranting inpatient hospitalization or suicide-focused treatment; and impaired mental status that precludes the ability to provide informed consent (e.g., intoxication, psychosis, mania).",{"count":88,"type":20},100,[23],"The long-term goal of this study is to reduce suicidal thoughts and behaviors among treatment-seeking individuals who also have posttraumatic stress disorder (PTSD). Prolonged exposure (PE) and crisis response plan (CRP) have demonstrated empirical support for reducing suicide attempts as compared to treatment as usual. However, no studies to date have assessed their effectiveness when used in combination. In light of this knowledge gap, the primary objective of this study will be to test the effectiveness of PE augmented with CRP as compared to PE with care as usual (self-guided treatment plan), an active comparator, for the reduction of suicide ideations and attempts for individuals with comorbid PTSD.",[92,26,93,94],"PTSD","Suicide, Attempted","Trauma, Psychological","2026-06-24",{"date":97,"type":36},"2026-06-29",{"date":99,"type":36},"2024-02-26",{"date":101,"type":20},"2027-06",{"name":103,"class":43},"Ohio State University",{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":44},"100596878","recovery-through-inspiration-support-and-empowerment-100596878","NCT07051200","Recovery Through Inspiration, Support, and Empowerment","RISE","Inclusion Criteria:\n\n* Chief complaint of suicidal ideation, suicide attempt, depression, and\u002For anxiety\n* discharged from inpatient care or from emergency department\n* men and women ages 18-27\n\nExclusion Criteria:\n\n* primary diagnosis of: substance use disorder, schizophrenia spectrum, intellectual development disorder, autism spectrum disorder (level II or III)","27 Years",{"count":113,"type":20},40,[23],"The goal of this pilot study is to test the effectiveness of a novel intervention for young adults (ages 18-27) with mental health conditions who have been released from an acute care psychiatric facility. The intervention aims to reduce suicidality, depression, anxiety, re-hospitalization, and improve mental health recovery by using outpatient services.\n\nThe current standard of care (SOC) for these patients at discharge includes a discharge plan with a list of their medications, anticipated outpatient appointments, and information on when and where to find community resources.\n\nThe intervention being tested involves the implementation of a mental health recovery education and support program, involving one-on-one and small group meetings led by Peer Support Specialists (PSS) and Recovery Community Organizations (RCO).\n\nParticipants will be assigned to either Cohort A or B for 8 weeks.\n\nCohort A will be the intervention group with PSS and RCOs.\n\n* Weeks 1-4: One-on-one meetings with PSS for education and support. Assessments will be completed at weeks 2 and 4.\n* Weeks 5 and 7: One-on-one meetings with PSS for education and support.\n* Week 6 and 8: Group meetings with PSS and other participants from RCOs. Assessments will be completed during these weeks.\n\nCohort B will be the SOC group with no PSS or RCOs.\n\n* Weeks 1-4: Weekly check in phone calls with a member of the research team. Assessments will be completed at weeks 2 and 4.\n* Weeks 5-8: Check in phone calls with a member of the research team every other week. Assessments will be completed at weeks 6 and 8.\n\nData collected from participant assessments, adherence to medication, and re-admittance to a psychiatric facility will be used to compare the intervention to the SOC.",[26,27,117,118],"Anxiety","Depression Disorders",[120,121,122,123,124,125],"Peer Support Specialist (PSS)","Recovery Community Organization (RCO)","Mental Health Recovery","Transitional Age Youth (TAY)","UT Southwestern Medical Center","Young Adult","2026-06-22",{"date":128,"type":36},"2026-06-25",{"date":130,"type":36},"2025-04-01",{"date":132,"type":20},"2027-12-01",{"name":134,"class":43},"University of Texas Southwestern Medical Center",{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":16,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":146,"conditions":147,"keywords":152,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":44},"100489364","inhibitory-mechanisms-of-negative-urgency-in-adolescent-suicidal-behavior-100489364","NCT05652153","Inhibitory Mechanisms of Negative Urgency in Adolescent Suicidal Behavior","Inclusion Criteria:\n\n* Ages 13-21 years (inclusive)\n* Any sex, gender, race, or ethnicity\n* For participants 18 years of age or older, ability to provide written informed consent\n* For participants under 18 years of age, ability to provide written assent, with legal guardian's ability to provide written informed consent\n* Ability of participant (and parent\u002Fguardian, if applicable) to read and to communicate verbally and in writing in English (in order to permit comprehensive assessment of suicide risk by study team, and to facilitate safety planning and mitigation of suicide-related risks as necessary)\n* Current diagnosis of a unipolar depressive episode (major depressive episode, unspecified depressive disorder, or adjustment disorder with depressed mood), confirmed on the structured diagnostic interview (MINI or MINI-Kid)\n* For participants in the Dep\u002FSI group:\n\n  * Any lifetime history of suicidal ideation, as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)\n  * No prior history of suicidal behavior (interrupted attempt, aborted attempt, or suicide attempt) as assessed by the C-SSRS\n* For participants in the Dep\u002FSB group:\n\n  \\-- Any lifetime history of suicidal behavior (interrupted attempt, aborted attempt, or suicide attempt) as assessed by the C-SSRS\n* If the study participant will be completing any of the assessments remotely through the use of video teleconferencing, access to a reliable internet connection will be required\n\nExclusion Criteria:\n\n* Imminent suicide risk as determined by the PI or other study board-certified child and adolescent psychiatrist (based on review of C-SSRS and SSI scales and clinical assessment of participant)\n* Current substance use meeting diagnostic criteria for a substance use disorder within the last month on the MINI or MINI-KID diagnostic interview (with the exceptions of caffeine and nicotine)\n* Lifetime history of psychosis, hypomania, or mania\n* Historical diagnosis of autism spectrum disorder or intellectual disability\n* Antiepileptic medication use or chronic benzodiazepine use (as-needed benzodiazepine use will be permitted if it can be held on day of study visit with TMS-EEG testing)\n* Pregnancy or suspected pregnancy in participants capable of becoming pregnant (assessed with urine pregnancy test)\n* Medical\u002Fneurologic history that would pose increased risks for transcranial magnetic stimulation (TMS) or magnetic resonance imaging (MRI), or factors that would impede completion of study procedures, including:\n\n  * Neurological disorders including seizure disorder, history of anoxia, history of head injuries with loss of consciousness for greater than 5 minutes\n  * Suicide attempt by hanging or strangulation (asphyxiation) leading to anoxia\n  * Any personal history of seizure or family history of epilepsy\n  * Any metallic implants, fragments, or devices\n  * Any cardiac pacemaker, medication pump, neural stimulator, or other implanted medical device\n  * Risk for increased intracranial pressure (e.g., history of intracranial mass)\n  * History of intracranial surgical procedure\n  * Any contraindication to TMS determined by the TMS Adult Safety Screen (TASS)\n  * Any contraindication to MRI identified on imaging center screening form\n* Any non-removable hair, head, or neck body modifications that would impede TMS and proper EEG recording","13 Years","21 Years",{"count":144,"type":20},80,[23],"The goal of this study is to understand why some people act more impulsively when feeling negative emotions, which is called negative urgency. The researchers hope to understand how negative urgency relates to the way networks of brain cells communicate with one another. The researchers will measure negative urgency and brain signals in adolescents aged 13-21 years with depression and suicidal thoughts and behaviors.\n\nThe main questions it aims to answer are:\n\n* Whether a type of brain signaling called cortical inhibition is related to negative urgency\n* Whether depressed adolescents with suicidal behavior have more problems with cortical inhibition than depressed adolescents with suicidal thoughts only\n* Whether the relationship between negative urgency and cortical inhibition changes over time\n\nAdolescents who participate in the study will complete the following activities at the time they join the study, as well as 6 months and 12 months later:\n\n* Interviews with researchers and questionnaires to learn about their thoughts, emotions, and symptoms\n* A questionnaire about impulsive behaviors and negative urgency\n* Computerized games that measure brain functions\n* An MRI scan of the brain\n* Transcranial magnetic stimulation with electroencephalography (TMS-EEG), a way to measure how brain cells communicate (cortical inhibition) using a magnet placed outside of the head and recording brain signals",[148,26,149,150,151],"Suicidal Behavior","Negative Urgency","Cortical Inhibition","Depression",[148,26,149,150,151,153,154,155],"Adolescent","Transcranial Magnetic Stimulation","Electroencephalography","2026-06-18",{"date":158,"type":36},"2026-06-23",{"date":160,"type":36},"2024-05-25",{"date":162,"type":20},"2028-01",{"name":164,"class":43},"University of Minnesota",{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":16,"minAge":141,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":177,"conditions":178,"keywords":184,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":44},"100642005","reward-sensitivity-digital-intervention-for-suicide-risk-100642005","NCT07661901","Reward Sensitivity Digital Intervention for Suicide Risk","Pilot Development of a Youth-Focused Digital Just-in-Time Adaptive Intervention to Enhance Reward Sensitivity and Reduce Suicidal Ideation","DIGIReward","Inclusion Criteria:\n\nADOLESCENTS\n\n* Aged 13-17 years old\n* Recent suicidal ideation\n* Access to a smartphone device\n* Residing in the Philadelphia metropolitan area\n\nLEGALGUARDIANS\n\n* They are the legal guardian of an adolescent that meets all study criteria (see above)\n* They can read, write, and speak English\n\nExclusion Criteria:\n\nADOLESCENTS\n\n* Psychotic disorder, including schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified, with a past year psychotic episode prior to baseline\n* Bipolar disorder I diagnosis, with a past year manic episode prior to baseline\n* Imminent suicide risk (e.g., active suicidal ideation with a specific plan and intent)\n\nLEGALGUARDIANS\n\n\\- There are no exclusion criteria for legal guardians","17 Years",{"count":175,"type":20},20,[23],"The goal of this clinical trial is to develop and test an app designed to reduce suicide risk and improve emotional well-being in adolescents. The study will test if the app's daily check ins and recommended mood boosting skills will improve the adolescent's overall mood and suicidality. The main question it aims to answer is:\n\n• Is the app practical and acceptable to use daily?\n\nIn the study, adolescents will:\n\n* Participate in a focus group with other adolescents and provide feedback on the app itself (design, ease of use, etc.).\n* Complete surveys and assessments on their mood, thoughts, and experiences.\n* Complete assessments about their app experience.\n\nIn the study, the legal guardian of the adolescent will:\n\n* Participate in a focus group with other adolescents and provide feedback on the app itself (design, ease of use, etc.).\n* Complete assessments about their app experience.",[26,179,180,181,182,183],"Suicidal","Suicidal Thoughts","Digital Health Intervention","Reward Sensitivity","Anhedonia",[185,186,187,188,29,189,190,191,182,183],"Adolescents","Legal Guardians","Digital","Philadelphia","Intervention","Prevention","Dyads","2026-06-16",{"date":126,"type":36},{"date":195,"type":20},"2026-06",{"date":197,"type":20},"2027-09",{"name":199,"class":43},"University of Pennsylvania",{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":207,"sex":16,"minAge":17,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":21,"phases":211,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":44},"100514357","recovers---realigning-emotion-and-cognition-via-precision-regulation-networks-100514357","NCT05977439","RECOVERS - Realigning Emotion and COgnition Via prEcision Regulation networkS","A Multiphase Program of Multimodal Computational Modeling and Hybrid Interventions Including EEG-Synchronized Transcranial Magnetic Stimulation and Cognitive Behavioral Therapy","Study 1 (Healthy Participants)\n\nInclusion Criteria:\n\n* Age 18-65 years\n* Medically and psychiatrically healthy with no history of psychiatric or neurological disorders\n* English-speaking\n* Capacity to provide informed consent\n* Willingness and ability to complete study procedures\n* Negative pregnancy test for participants of childbearing potential\n\nExclusion Criteria:\n\n* Any current or past psychiatric diagnosis\n* Neurological disorders or history of central nervous system disease\n* History of seizure or epilepsy or use of medications that lower seizure threshold\n* Significant head injury or loss of consciousness\n* Implanted metal or contraindications to MRI or TMS\n* Substance use disorder (excluding nicotine or caffeine)\n* Pregnancy or plans to become pregnant during study participation\n* Inability to complete study procedures\n\nStudies 2, 3, and 4 (Participants with Depression)\n\nInclusion Criteria:\n\n* Age 18-65 years\n* Current diagnosis of Major Depressive Disorder (MDD)\n* Depression severity consistent with study criteria (e.g., HAM-D ≥ 17)\n* No history of psychotic or bipolar disorders\n* English-speaking\n* Capacity to provide informed consent\n* Willingness and ability to complete study procedures\n* Negative pregnancy test for participants of childbearing potential\n\nExclusion Criteria:\n\n* Neurological disorders or history of central nervous system disease\n* History of seizure or epilepsy or use of medications that lower seizure threshold\n* Significant head injury or loss of consciousness\n* Implanted metal or contraindications to MRI or TMS\n* Substance use disorder (excluding nicotine or caffeine)\n* Current participation in another interventional clinical trial\n* Pregnancy or plans to become pregnant during study participation\n* Any condition that would interfere with safe participation or completion of study procedures",true,"65 Years",{"count":210,"type":20},120,[23],"In this research study, investigators examine how brain activity changes during tests of emotional processing, attention, and memory using multimodal neuroimaging methods including electroencephalography (EEG), functional magnetic resonance imaging (fMRI), and functional near-infrared spectroscopy (fNIRS). Transcranial magnetic stimulation (TMS) is used to probe and modulate brain networks related to cognitive flexibility and emotion regulation.\n\nThe study includes multiple related sub-studies involving healthy participants and participants with depression. Some study components focus on mechanistic modeling using non-therapeutic neurostimulation in healthy participants, while other components include interventional approaches such as individualized EEG-synchronized repetitive TMS (rTMS), cognitive tasks, and brief cognitive behavioral therapy (CBT) in participants with depression. Certain study components also evaluate CBT alone without TMS to assess behavioral intervention effects.",[151,214,26],"Major Depressive Disorder",[216,217,218,219,220,221,222],"transcranial magnetic stimulation","EEG-synchronized rTMS","closed-loop neurostimulation","depression","suicide prevention","cognitive behavioral therapy (CBT)","neuroplasticity","2026-06-12",{"date":192,"type":36},{"date":226,"type":36},"2024-02-01",{"date":228,"type":20},"2028-10-01",{"name":230,"class":43},"Medical University of South Carolina",{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":207,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":240,"phases":4,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":44},"100642300","user-evaluation-think-life-100642300","NCT07654127","User Evaluation Think Life","Evaluation of User Experiences With the Online Self-help Course Think Life","Inclusion Criteria:\n\n* age: 18 years or older\n* user of the online self-help course Think Life\n\nExclusion Criteria:\n\n* not meeting the inclusion criteria",{"count":239,"type":20},1000,"OBSERVATIONAL","This study aims to evaluate user experiences with the online self-help course Think Life, a suicide prevention intervention for individuals experiencing suicidal thoughts. Think Life was developed by the Flemish Centre of Expertise in Suicide Prevention (VLESP) and is freely available via Zelfmoord1813.be. The course was originally developed in 2014 and updated in 2025 to improve its look and feel, usability, and inclusiveness, without fundamental changes to its core content.\n\nThe researchers seek to better understand how users experience the updated version of Think Life, including perceived strengths, usability, and overall satisfaction with the course.\n\nUsers of the Think Life self-help course will be invited through a call displayed on the course homepage to voluntarily participate in an online user evaluation study. Interested individuals can access an online informed consent form via a public internet link hosted on REDCap. Participants who provide online informed consent and meet the inclusion criteria will automatically be redirected to the online questionnaire, which is also hosted on REDCap.\n\nApproximately 1000 participants aged 18 years or older can be included in this study. Participants are invited to complete a one-time online questionnaire with an estimated completion time of approximately 10 minutes.",[26,243,244],"Suicide Prevention","mHealth Intervention","2026-06-11",{"date":247,"type":36},"2026-06-17",{"date":249,"type":20},"2026-06-01",{"date":251,"type":20},"2031-06-01",{"name":253,"class":43},"University Ghent",{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":207,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":240,"phases":4,"briefSummary":264,"conditions":265,"keywords":269,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":4},"100641745","student-precarity-and-psychiatry-100641745","NCT07618208","Student Precarity and Psychiatry","Impact of Precarity on the Emergence of Psychiatric Disorders and the Use of Care Among Students","PEPSY","Inclusion Criteria:\n\n* Student enrolled at Paris Sciences et Lettres University (PSL, 17,000 students) or the Faculty of Health Sciences at Paris Cité University (UPC, 28,000 students),\n* Aged 18 or over,\n* Fluent in French,\n* Affiliated to a health insurance.\n\nExclusion Criteria:\n\n* Applicants under the age of 18,\n* Not enrolled at PSL universities or the UPCS Faculty of Health,\n* Insufficient level of French.",{"count":263,"type":20},45000,"Since the COVID-19 pandemic, mental health disorders have increased significantly, particularly among young people. In France, the proportion of young people aged 18 to 25 suffering from depression almost doubled between 2017 and 2021. This phenomenon particularly affects students, who are already identified as being at greater risk of mental health disorders than the general population. Medical students seem to be particularly vulnerable: in 2021, a national study showed very high rates of depression and suicidal thoughts in this population. The main factor associated with depression was the feeling of financial hardship.\n\nStudents often face multiple forms of insecurity. Financially, they have limited resources and struggle to cover their basic needs such as housing, food and healthcare. Socially, many experience significant isolation, particularly when they are away from their families or under pressure from their studies. All of this has a significant impact on their mental health. Unfortunately, many students do not seek help due to lack of time, resources, or awareness of support services. The 2021 study showed that only one-third of medical students suffering from depression received appropriate treatment.\n\nThe aim of our study is to assess the impact of precariousness on the onset of psychiatric disorders and on the use or non-use of healthcare services.\n\nOur study will involve nearly 45,000 students from PSL and UPC universities. It is based on a longitudinal cohort (via questionnaires) over three years. The aim is to identify precisely the different aspects of student precariousness (housing, transport, isolation, economic difficulties, etc.) and their link with psychological distress. The study will measure the extent of the phenomenon and identify modifiable factors that could be targeted by preventive measures. The results will enable us to better target preventive measures and propose concrete solutions to improve students' well-being and promote their success.",[266,267,26,268],"Depressive Disorder, Major","Generalized Anxiety Disorder","Loneliness",[270,151,271,272],"Students","Use of care","Precarity",{"date":274,"type":36},"2026-06-15",{"date":276,"type":20},"2026-09",{"date":278,"type":20},"2028-11",{"name":280,"class":43},"Assistance Publique - Hôpitaux de Paris",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":207,"sex":16,"minAge":289,"maxAge":208,"enrollmentInfo":290,"targetDuration":4,"studyType":21,"phases":292,"briefSummary":293,"conditions":294,"keywords":297,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":313},"100586887","exploratory-analysis-of-interpersonal-and-intrapersonal-psychological-processes-implied-in-risk-taking-and-suicidal-behaviors-in-adult-and-adolescent-at-risk-100586887","NCT06921226","Exploratory Analysis of Interpersonal and Intrapersonal Psychological Processes Implied in Risk-taking and Suicidal Behaviors, in Adult and Adolescent At-risk","Intra-personal and Interpersonal Psychological Processes Involved in Risk-taking and Suicidal Behaviors Among Vulnerable Adolescents and Adults","RISKY","Inclusion Criteria:\n\n* Age 12-65 years\n* Adolescent population considered as at risk in mental health : admitted to the peadiatric department (CHMS).\n\nor - Adult population : user of the Espoir73 association (an association for adults with a mental health problem) or users of SM@RT (CHS, a psycho-social rehabilitation center for adults with a mental illness).\n\nExclusion Criteria:\n\n\\- No suicidal ideation or behaviors (none \" Yes \" response at the 6 questions of the C-SSRS screen version).","12 Years",{"count":291,"type":20},1400,[23],"In a recent report, Santé Publique France (2023), reported that 4.2% of 18-85 year-olds had thought about suicide in the last 12 months, and 6.8% had attempted suicide in their lifetime and 0.5% in the last year. Even more recently, the DREES (Direction de la recherche, des études, de l'évaluation et des statistiques auprès des Ministères Sociaux) published a report on May 16, 2024, showing a sharp rise in hospitalization rates for self-inflicted acts among female patients aged between 10 and 24, with a peak around age 15. Two-thirds of these hospitalizations for self-inflicted injuries are related to deliberate drug intoxication. Depression, bipolar disorders and schizophrenia spectrum disorders (among other psychological disorders) are known risk factors for suicide, which is the leading cause of death in this clinical context. In addition to these formalized psychopathological elements, risk behaviors underpinned by psychological processes common to suicide attempts are suspected and need to be studied in depth.\n\nResearch into psychiatry and the psychopathology of suicide has identified a number of risk and protective factors. These psychological determinants - or processes - act alongside other key factors such as the environment and social ties. Life contexts can have an impact on health, and more specifically on the psychopathology of individuals, through disturbances of a biological, psychological and social nature. It is important to be able to describe what processes are at work and how they explain the development and maintenance of behaviours that put one's life and health at risk. This is part of a preventive approach to mental health. We suggest that the study of psychological processes such as suicidal ruminations, impulsivity and interpersonal needs (e.g. the interpersonal theory of suicide) is necessary to understand their involvement in risk-taking and suicidal behavior. To our knowledge, few studies of this type are underway in France, particularly with vulnerable clinical populations (adolescents\u002Fadults). The inclusion of a process-centered approach (Kinderman, 2015), in a transdiagnostic and preventive way, constitutes an innovative approach.",[295,26,296],"Suicidal Ideas","Risk-taking",[298,299,300,301,302,303],"Risk-taking behaviors","Impulsivity","Interpersonal needs","Suicidal ruminations","Suicidal behaviors","BART","2026-06-09",{"date":306,"type":36},"2026-06-10",{"date":308,"type":36},"2025-06-26",{"date":310,"type":20},"2027-06-26",{"name":312,"class":43},"Centre Hospitalier Metropole Savoie",3,{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":16,"minAge":322,"maxAge":17,"enrollmentInfo":323,"targetDuration":4,"studyType":21,"phases":324,"briefSummary":325,"conditions":326,"keywords":327,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":339,"leadSponsor":341,"locationsCount":44},"100642442","brief-crisis-therapy-for-suicidal-children-and-adolescents-100642442","NCT07627243","Brief Crisis Therapy for Suicidal Children and Adolescents","Ultra-Brief Crisis IPT-A Based Intervention for Suicidal Children and Adolescents (IPT-A-SCI): Understanding Mechanisms of Change","IPT-A-SCI","Inclusion Criteria:\n\n* Children and adolescents aged 8-18 years presenting with suicidal ideation or behavior\n* Suicide risk assessment indicating suitability for outpatient treatment,\n* Fluency in Hebrew\n* Ability to attend five weekly treatment sessions\n* Written informed consent provided by parents or legal guardians\n* Written informed assent\u002Fconsent provided by participants in accordance with age and local ethical regulations\n\nExclusion Criteria:\n\n* Acute medical or psychiatric condition requiring immediate inpatient treatment\n* Linguistic, developmental, neurological, or intellectual limitations that prevent understanding of the treatment protocol or study procedures\n* Inability to participate in outpatient psychotherapy","8 Years",{"count":210,"type":20},[23],"The goal of this clinical trial is to learn if the Ultra-Brief Interpersonal Psychotherapy for Adolescents with Suicidal Ideation (IPT-A-SCI) works to reduce suicidal thoughts and behaviors in children and adolescents. The study will also examine whether treatment effects continue after treatment ends and whether some participants benefit more from the intervention than others. The main questions it aims to answer are:\n\nDoes IPT-A-SCI reduce suicidal thoughts and behaviors in children and adolescents? Do the effects of IPT-A-SCI continue three months after treatment ends? Do some children and adolescents benefit more from IPT-A-SCI than others?\n\nParticipants will:\n\nReceive IPT-A-SCI treatment consisting of five weekly sessions Complete questionnaires before treatment, during treatment, at the end of treatment, and three months after treatment ends Have their parents complete questionnaires at the same time points",[26,148],[328,329,330,331,332,333,334,335],"suicidal ideation","suicidal behavior","Interpersonal psychotherapy","children","adolescents","Suicide prevention","Safety planning","Brief intervention","2026-06-08",{"date":245,"type":36},{"date":195,"type":20},{"date":340,"type":20},"2028-06",{"name":342,"class":43},"Tel Aviv University",{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":21,"phases":351,"briefSummary":352,"conditions":353,"keywords":358,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":44},"100575899","transition-health-and-resilience-through-valued-experiences-thrive-pilot-for-newly-separated-veterans-100575899","NCT06778278","Transition Health and Resilience Through Valued Experiences (THRiVE) Pilot for Newly Separated Veterans","Adapting Behavioral Activation to Improve Mental Health Outcomes and Reduce Suicide Risk During the Military Transition","Inclusion Criteria:\n\n* Be either (a) a United States military veteran who separated no more than 12 months prior to study enrollment or (b) a United States transitioning service member on terminal leave\n* Be at least 18 years old\n* Have access to the internet; a desktop computer, laptop, tablet, or other \"smart\" device with video camera, speakers, and microphone; and a private place from which to attend THRiVE sessions\n* Reside and complete all study activities within the United States\n\nExclusion Criteria:\n\n* Endorse lifetime manic, hypomanic, or psychotic episodes\n* Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for current severe alcohol use disorder or substance use disorder (except for tobacco use disorder, which will not be exclusionary)\n* Screen positive for moderate or high acute risk for suicide\n* Screen positive for more than minimal risk for other-directed violence\n* Are receiving or plan to receive BA therapy for any mental health condition between enrollment and the 3-month follow-up assessment",{"count":113,"type":20},[23],"The objective of this study is to develop and pilot a program designed to improve mental health outcomes and reduce suicide risk during the transition from military to civilian life. It is hypothesized that the Transition Health and Resilience through Valued Experiences (THRiVE) program, to be developed as part of this study, will meet participant recruitment, retention, and satisfaction benchmarks (primary outcomes) and show positive preliminary effects on mental health symptoms, risk factors for suicidal ideation, and psychosocial functioning outcomes (secondary outcomes).\n\nThe specific aims of this study are to:\n\n1. Develop a small-group, peer-led, cross-cutting prevention program for newly separated veterans (NSVs) called THRiVE and\n2. Evaluate the feasibility, acceptability, and preliminary effects of the THRiVE program on mental health symptoms, risk factors for suicidal ideation, and psychosocial functioning outcomes.\n\nUp to 40 NSVs participating in this Stage 1 pilot study will complete validated self-report measures at baseline, immediately after completing the THRiVE program (post-THRiVE), and 3 months after completing the THRiVE program (follow-up). The duration of a participant's time in the study is anticipated to be 5 months.",[354,355,356,26,357],"Military Transition","Community Reintegration","Mental Health","Alcohol Misuse",[359,360,361,362,363,364],"Military transition","Community reintegration","Mental health","Suicidal ideation","Transitioning Service Members","Newly separated Veterans",{"date":306,"type":36},{"date":367,"type":36},"2025-07-30",{"date":369,"type":20},"2026-10-31",{"name":371,"class":43},"RTI International",{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":207,"sex":16,"minAge":289,"maxAge":380,"enrollmentInfo":381,"targetDuration":4,"studyType":21,"phases":383,"briefSummary":384,"conditions":385,"keywords":386,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":44},"100489521","wecare-a-system-of-care-for-black-youth-100489521","NCT05654207","WeCare: A System of Care for Black Youth","Answering the Alarm: A System of Care for Black Youth at Risk for Suicide","WeCare","Inclusion criteria adolescent and parent\u002Fguardians:\n\n* Adolescents aged 12-17 years and their parents or guardians, and adolescents 18-19 years who have the option for their parent or guardian to participate\n* Having a parent\u002Fcaregiver present in the ED to consent or available to consent remotely (12-17 year olds, only)\n* Having a cellular phone with text messaging capacity\n* Adolescent able to speak English, and understand study questions\n* Parents able to consent in English, Spanish, French or Creole\n* Meet screening criteria\n\nExclusion criteria adolescent and parent\u002Fguardians:\n\n* Adolescent is medically unstable\n* Adolescent present with severe cognitive impairment\n* Parents are not present in the ED, unable to consent remotely, and not able to give consent in either English, Spanish, French or Creole (12-17 year olds, only)\n* Adolescent does not have access to cellular phone\n* Adolescents active in mental health treatment (e.g., seen a therapist, social worker, or mental health provider in the last week)","19 Years",{"count":382,"type":20},2200,[23],"The overall goal of this study is to respond to the urgent need for an effective suicide prevention strategy for Black youth by examining the effectiveness of a systems-level strategy to recognize and respond to suicide risk among Black adolescents who present to emergency departments (EDs). The proposed strategy, WeCare, combines combines three components: (1) universal screening using the Computerized Adaptive Screen for Suicidal Youth (CASSY), (2) a brief intervention designed for Black youth with elevated suicide risk in for ED settings, Connections for Safety (CFS), that combines safety planning and strategies to support linkage to outpatient mental health services, and (3) supportive text messages to youth and parent\u002Fcaregivers for six weeks following the youth's ED visit. Study objectives are (1) to integrate input from multiple stakeholders to inform and facilitate WeCare implementation, and (2) to use a hybrid one effectiveness-implementation design to evaluate its effectiveness.",[26],[387,388,389,219],"suicide","ideation","Black youth",{"date":306,"type":36},{"date":392,"type":36},"2024-04-08",{"date":394,"type":20},"2027-04-01",{"name":396,"class":43},"New York University",{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":16,"minAge":289,"maxAge":173,"enrollmentInfo":404,"targetDuration":4,"studyType":21,"phases":406,"briefSummary":407,"conditions":408,"keywords":412,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":423,"leadSponsor":425,"locationsCount":44},"100640620","youth-suicide-prevention-cams-bi-vs-safety-planning-in-a-randomized-trial-100640620","NCT07628192","Youth Suicide Prevention: CAMS-BI vs. Safety Planning in a Randomized Trial","Innovating Suicide Preventative Care for Youth; A Randomized Trial of CAMS- BI Versus Stanley- Brown Safety Planning Intervention in Preventing Suicide Driven Readmission","Inclusion Criteria:\n\n* Adolescents aged 12-17 years.\n* Admitted to inpatient psychiatry for suicide attempt or active suicidal ideation.\n* English-speaking patient and parent\u002Fguardian.\n* Ability to understand and the willingness to sign a written informed assent document with a parent\u002Fguardian willing and able to sign a written informed consent.\n\nExclusion Criteria:\n\n* Moderate or severe intellectual disability (IQ less than 70 and those patients in special education classes full time).\n* Schizophrenia or history of any type of psychosis including mood related psychosis and brief reactive psychosis.\n* In custody of Children's Services.",{"count":405,"type":20},118,[23],"This study outlines a randomized controlled trial evaluating two brief suicide-specific interventions for adolescents aged 12-17 who are hospitalized for suicidal ideation or attempts. Suicide remains a leading cause of death among youth, and many adolescents are discharged from inpatient care without targeted, suicide-focused treatment, contributing to high rates of readmission and ongoing risk. This study seeks to address that gap by comparing the effectiveness of the Collaborative Assessment and Management of Suicidality-Brief Intervention (CAMS-BI) with the Stanley-Brown Safety Planning Intervention (SPI), both delivered as single-session interventions during inpatient hospitalization.\n\nParticipants (N=118) will be randomly assigned to receive either CAMS-BI or SPI. CAMS-BI is a therapeutic, collaborative framework that focuses on identifying and addressing the underlying psychological drivers of suicidality, while SPI is a structured, practical approach that emphasizes immediate safety through coping strategies, support systems, and means restriction. Following the intervention, participants will be monitored for 90 days post-discharge, with follow-ups at 30, 60, and 90 days.\n\nThe primary outcome is the rate of psychiatric readmissions and suicide-related emergency department visits within 90 days of discharge. Secondary outcomes include changes in suicidal ideation, measured by the Beck Scale for Suicide Ideation, and caregiver confidence in managing their child's safety. Additional measures include distress levels, hopelessness, treatment satisfaction, and engagement.\n\nThe study hypothesizes that CAMS-BI will result in lower readmission rates, greater reductions in suicidal ideation, and improved caregiver confidence compared to SPI. Both interventions produce individualized safety or stabilization plans that are shared with patients and caregivers and incorporated into discharge planning to support continuity of care.\n\nSafety protocols are emphasized throughout the study, given the high-risk population. Participants receive standard clinical care, crisis resources, and close monitoring, with procedures in place to address any escalation in suicide risk. Data will be collected using secure systems, and confidentiality will be maintained through de-identification and controlled access.\n\nOverall, this study aims to determine whether a rapid, inpatient, suicide-focused intervention can improve short-term outcomes for high-risk youth and reduce the likelihood of rehospitalization, ultimately informing scalable approaches to suicide prevention in clinical settings.",[26,27,409,410,411],"Safety Plan","Depression \u002F Major Depressive Disorder","Hopelessness",[413,414,415,416,151,417,418,411],"Youth suicide","Suicide ideation","Suicide attempt","Suicidal behavior","CAMS therapy","Safety plan","2026-06-03",{"date":421,"type":36},"2026-06-04",{"date":75,"type":20},{"date":424,"type":20},"2027-03-01",{"name":426,"class":43},"The Cleveland Clinic",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":16,"minAge":434,"maxAge":435,"enrollmentInfo":436,"targetDuration":4,"studyType":240,"phases":4,"briefSummary":438,"conditions":439,"keywords":442,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":44},"100616444","climate-anxiety-in-a-young-population-at-risk-of-suicide-100616444","NCT07305688","Climate Anxiety in a Young Population at Risk of Suicide","Anx-RS","Inclusion Criteria:\n\n* Men and women, boys and girls ;\n* Aged between 16 and 24;\n* Participants seen in adult or pediatric emergency departments, hospitalised in adult psychiatry or in child and adolescent psychiatry, or seen in outpatient consultation at Esquirol Hospital Center ;\n* Affiliated with a social security scheme or entitled to coverage under one ;\n* Having received full information about the study and having co-signed, together with the investigator, an informed consent form to participate in the study.\n* For minor participants: the consent to participate in the study must be signed by the holder(s) of parental authority, and the minor's assent will also be required.\n\nExclusion Criteria:\n\n* Participants will not be included in the study if their health condition is incompatible with understanding or completing the questionnaires used. This includes, in particular ;\n* Any chronic somatic pathology or major sensory impairment (for example : deafness or blindness) preventing reading, comprehension or communication with healthcare professionals ;\n* Any severe psychiatric pathology that significantly impairs cognitive or communication abilities, such as acute psychotic disorders, pervasive developmental disorders or confusional states ;\n* Participants hospitalised in units specialising in severe psychiatric disorders with major impairment of cognitive functions.\n* Adults under legal protection, in accordance with article L 1121-8 of the Public Health Code ;\n* Insufficient command of the French language","16 Years","24 Years",{"count":437,"type":20},108,"Climate change has become a major source of concern, particularly among younger generations who are facing the progressive degradation of ecosystems, loss of biodiversity, and alarming environmental information disseminated through the media. The direct perception of climate-related disruptions has been shown to engender a profound sense of helplessness and loss. This distress, termed eco-anxiety, is characterised by feelings of fear, sadness and guilt regarding the planet's future.\n\nIn a context where there has been a marked increase in suicidal thoughts and attempts among young people over the past decade, it is essential to explore the psychological manifestations of eco-anxiety within this vulnerable population. The paucity of studies investigating this association underscores the significance of the present research.\n\nThe aims of this study is to examine the relationship between climate anxiety and suicidal risk among young people aged 16 to 24 years.\n\nThe study will encompass 108 young participants aged between 16 and 24 years, who are either hospitalised or receiving outpatient psychiatric care.\n\nEach participant will be required to complete one clinician-administered assessment, namely the Columbia Suicide Severity Rating Scale (C-SSRS), and two self-report questionnaires: the Climate Change Anxiety Scale - French version (CCAS-FR) and the State-Trait Anxiety Inventory (STAI-Y).\n\nFurthermore, a sociodemographic questionnaire will be administered in order to collect information regarding the subjects' age, sex, education level, living conditions, and psychiatric history.\n\nIt is hypothesised that there is a positive association between climate anxiety and suicidal risk, with the most eco-anxious participants showing higher C-SSRS scores. It is further predicted that eco-anxiety will correlate with elevated levels of state and trait anxiety, with the potential for modulating this relationship by sociodemographic factors, including gender.\n\nThis study will contribute to a better understanding of the psychological impacts of climate change on young people and help identify the most vulnerable profiles.",[117,26,440,441],"Mental Health Issue","Environmental Exposure",[443,444,445,361,446],"Eco-anxiety","Anxiety disorders","Suicide risk","Young adults","2026-06-02",{"date":421,"type":36},{"date":450,"type":36},"2025-12-15",{"date":452,"type":20},"2027-03-15",{"name":454,"class":43},"Centre Hospitalier Esquirol",{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":16,"minAge":289,"maxAge":17,"enrollmentInfo":462,"targetDuration":4,"studyType":21,"phases":463,"briefSummary":464,"conditions":465,"keywords":466,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":44},"100401093","sequential-bilateral-accelerated-theta-burst-stimulation-in-adolescents-with-suicidal-ideation-100401093","NCT04502758","Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation","A Randomized Controlled Trial of Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation Associated With Major Depressive Disorder","Inclusion Criteria:\n\n* Inpatients or outpatients\n* Voluntary clinical patient with the capacity to assent to treatment and a parent or legal guardian with the capacity to consent\n* Female or male\n* 12-18 years of age\n* Diagnosed with MDD based on Diagnostic and Statistical Manual for Mental Disorders, 5th edition (DSM-5) criteria122 with the Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI Kid) in subjects 12-17 years of age;118 The Mini-International Neuropsychiatric Interview will be used for subjects who are 18 years of age117\n* In a current episode of MDD with duration of at least 4 weeks but less than 3 years\n* Depressive symptom severity as demonstrated by CDRS-R total composite score of 40 or greater and a suicidal ideation score of 3 or more on item 13 of the CDRS-R109\n* Demonstrating that depressive symptom severity as evaluated at the screening visit does not improve between screening and baseline by 25% or more\n* Eligible for transcranial magnetic stimulation (TMS) based on safety criteria104\n* On a medically acceptable form of birth control if female\n* Taking an antidepressant medication if recommended by the referring clinician and agreed upon by parents and patients. Please note that patients are not required to take an antidepressant medication for study participation for practical, ethical, and human subject protection concerns. Medication status and prior treatment resistance will be carefully recorded with the Antidepressant Treatment History Form113 criteria for relevant statistical considerations.\n\nExclusion Criteria:\n\n* Diagnosis of a psychotic disorder, bipolar disorder, anorexia nervosa, bulimia nervosa, substance use disorders within the past year (with the exception of caffeine and tobacco).\n* Intelligent quotient less than 70 (if there is a clinical concern, subjects will be psychometrically assessed with the Slosson Intelligence Test, Revised).123\n* Positive urine drug screen at baseline\n* Seizure history\n* Any family history of epilepsy\n* History of any treatment with electroconvulsive therapy or TMS\n* Use of any investigational drug within 4 weeks of baseline\n* Prior brain surgery\n* Risk for increased intracranial pressure such as a brain tumor\n* Head trauma with loss of consciousness\n* Any true positive findings on the TMS safety screening form\n* Pregnancy or suspected pregnancy\n* Conductive, ferromagnetic, or other magnetic-sensitive metals implanted in the head-within 30 cm of the treatment coil excluding the mouth that cannot be safely removed (examples include cochlear implants, vagus nerve stimulators, deep brain stimulators, implanted electrodes\u002Fstimulators, aneurysm clips or coils, stents, bullet fragments, jewelry and hair barrettes).\n* Implanted medication pumps and cardiac pacemakers\n* Any unstable medical condition\n* Inability to adhere to the protocol",{"count":144,"type":20},[23],"The purpose of this study is to gather information regarding the use of a new type of transcranial magnetic stimulation (TMS) called theta burst stimulation (TBS) for suicidal ideation in adolescents with Major Depressive Disorder (MDD). The investigators hope to learn if this TMS treatment improves suicidal ideation over 10 days and clinical outcomes over 1 year of follow-up.",[26,214],[153],"2026-05-28",{"date":249,"type":36},{"date":470,"type":36},"2022-04-04",{"date":472,"type":20},"2027-12",{"name":474,"class":43},"Mayo Clinic",{"id":476,"slug":4,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":21,"phases":479,"briefSummary":57,"conditions":480,"keywords":481,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":485,"leadSponsor":486,"locationsCount":80},"100636169","Inclusion Criteria:\n\n* 18 years or older, capable of making decisions, and able to provide informed consent.\n* Major Depressive Disorder (MDD) according to DSM-5 criteria\n* Current depressive episode of moderate to severe intensity\n* Episode duration of at least two weeks\n* Baseline MADRS score ≥ 20\n* No treatment changes (including antidepressants) in the 4 weeks prior to the study\n* Abstain from psychedelics ≥14 days before dosing (D0) and during the 12-month follow-up\n\nExclusion criteria:\n\n* Major cardiac, hepatic, or renal disease; unstable cardiovascular conditions\n* Uncontrolled hypertension, QTc prolongation, arrhythmias, or valvular disease COPD or asthma\n* Severe obesity, uncontrolled diabetes, coagulopathy, thyroid disease, or glaucoma\n* Neurological risk (e.g., aneurysm, ↑ICP, epilepsy\u002Fseizures, severe disorders)\n* MAO deficiency or history of serotonin syndrome\n* Pregnant, breastfeeding, positive test, or no effective contraception\n* Secondary depression\n* Cluster B personality disorders (incl. borderline with ≥2 suicidal behaviors in past 12 months) or poor therapeutic rapport\n* Psychotic disorders, MDD with psychotic features, or first-degree family history of psychosis\u002Fbipolar disorder\n* Mania\u002Fhypomania (YMRS ≥8)\n* OCD, dissociative disorders, active PTSD, or decompensated eating disorders\n* Moderate-severe use disorder (past 6 months; except nicotine\u002Fcaffeine)\n* Lifetime ketamine, PCP, psychedelics, or MDMA use disorder\n* Current use of MAO inhibitors, unless discontinued at least 14 days prior to dosing\n* Psychedelic trial participation in past 12 months\n* Cognitive impairment affecting valid assessment",{"count":54,"type":20},[56],[59,60,61,26,29],[63,64,65,66,67,68,69,70],"2026-05-22",{"date":467,"type":36},{"date":75,"type":20},{"date":77,"type":20},{"name":79,"class":43},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":495,"enrollmentInfo":496,"targetDuration":4,"studyType":21,"phases":498,"briefSummary":499,"conditions":500,"keywords":504,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":517,"locationsCount":44},"100626690","mind-after-midnight-100626690","NCT07438912","Mind After Midnight","The Mind After Midnight: Mechanistic Examination of Nocturnal Wakefulness as a Suicide Risk Factor","MaM","Inclusion Criteria\n\n* Age 18-55 years\n* History of suicidal ideation within the past 6 months\n* Habitual bedtime between 9:00 PM and 1:00 AM\n* Habitual wake time between 6:00 AM and 9:00 AM\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Current suicidal intent requiring immediate clinical intervention\n* Diagnosis of a primary sleep disorder (e.g., untreated obstructive sleep apnea, narcolepsy)\n* Bipolar disorder or psychotic disorder\n* Substance use disorder within the past 3 months\n* Use of medications that significantly affect sleep or circadian rhythms\n* Night shift work or transmeridian travel within the past month\n* Medical or neurological condition that would interfere with participation\n* Pregnancy","55 Years",{"count":497,"type":20},90,[23],"This study examines whether wakefulness during the biological night (2:00-4:00 AM) is associated with increased negative mood, impaired decision-making, and suicidal thoughts. Adults with a history of suicidal ideation in the past six months will complete laboratory and home-based assessments under varying levels of sleep pressure. Participants will be evaluated during late-night wakefulness and under conditions of both higher and lower sleep pressure. The goal of the study is to better understand the biological and behavioral mechanisms that may contribute to elevated suicide risk during nocturnal wakefulness.",[26,501,502,503],"Circadian Rhythm Disorders","Sleep Deprivation","Sleep Wake Disorders",[505,506,507,299,508,509,510,511],"Nocturnal Wakefulness","Suicide Risk","Circadian Misalignment","Mood Regulation","Biological Night","Sleep Pressure","Decision-Making","2026-05-19",{"date":482,"type":36},{"date":515,"type":36},"2026-03-06",{"date":40,"type":20},{"name":518,"class":43},"University of Arizona",{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":208,"enrollmentInfo":526,"targetDuration":4,"studyType":21,"phases":528,"briefSummary":530,"conditions":531,"keywords":532,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":44},"100584588","phase-2-understanding-and-treating-suicidal-ideation-with-ketamine-100584588","NCT06891300","Understanding and Treating Suicidal Ideation With Ketamine","Understanding and Treating Suicidal Ideation With Ketamine: A Diffusion Magnetic Resonance Imaging Study","Inclusion Criteria:\n\n1. English speaking\n2. Ages 18-65 years old\n3. Suicidal ideation severity score ≥3 on the Columbia Suicide Severity Rating Scale (C-SSRS) (Baseline\u002FScreening version) at Screening Visit (\"active suicidal ideation with any methods\")\n4. Diagnosis of Major Depressive Disorder (MDD) according to the Diagnostic and Statistical Manual for Mental Disorders 5th Edition (DSM-5)\n5. Willing to maintain stable doses of concomitant medications throughout the study\n6. Be under the care of a designated health care provider (i.e., family physician or psychiatrist) to follow their care after the completion of the study.\n\nExclusion Criteria:\n\n1. Participants not medically cleared to receive ketamine treatment due to presence of clinically relevant disease (e.g., uncontrolled hypertension, renal or hepatic impairment, significant coronary artery disease, diabetes mellitus, seizure disorder).\n2. Known or suspected hypersensitivity or intolerance to ketamine\n3. Body mass index (BMI) ≥35\n4. History of a primary psychotic disorder (e.g., schizophrenia), or current or recent (\\\u003C2 years) acute episode of psychosis\n5. Current and\u002For recent history (\\\u003C12 months) of substance use\u002Fdependence (except for caffeine or nicotine) or problematic current alcohol use or dependence as defined by DSM-5 criteria\n6. Pregnant, breastfeeding or of childbearing potential and unwilling to use an approved method of contraception during the study\n7. History of significant head injury including loss of consciousness \\>5 minutes\n8. Any MRI contraindications\n9. Concurrent use of ketamine in any form\n10. Concurrent active ECT or repetitive transcranial magnetic stimulation (rTMS) therapy",{"count":527,"type":20},36,[56,529],"PHASE3","The goal of this clinical trial is to treat active suicidal ideation in individuals with Major Depressive Disorder (MDD) using ketamine and to understand suicidal ideation by examining biological mechanisms using magnetic resonance imaging (MRI), and psychological mechanisms through validated clinical scales and qualitative interviews. The main questions it aims to answer are:\n\n1. Will ketamine will reduce suicidal ideation in a significant proportion of study participants?\n2. Will reduction in suicidal ideation will be accompanied by rapid changes in neuroimaging biomarkers?\n\nParticipants will receive four intravenous (IV) ketamine infusions administered twice weekly for two weeks. Participants will undergo two identical MRI scans: 1) within 48 hours prior to starting ketamine treatment, and 2) 24 hours after the fourth ketamine infusion. Suicidal ideation and depressive symptoms will be assessed prior to each imaging session alongside additional self-report measures. Qualitative interviews will occur within 72 hours after the fourth ketamine treatment.",[26,60],[214,26,533,534],"Ketamine","Neuroimaging","2026-05-15",{"date":512,"type":36},{"date":538,"type":36},"2025-04-08",{"date":540,"type":20},"2026-10",{"name":542,"class":43},"The Royal's Institute of Mental Health Research",{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":549,"eligibilityCriteria":550,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":551,"enrollmentInfo":552,"targetDuration":4,"studyType":21,"phases":553,"briefSummary":554,"conditions":555,"keywords":557,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":571},"100625085","preliminary-trial-of-an-avatar-guided-digital-intervention-for-emerging-adults-100625085","NCT07418047","Preliminary Trial of an Avatar Guided Digital Intervention for Emerging Adults","Randomized Controlled Feasibility Trial of an Avatar Guided Intervention for Young Adults Seen in the Emergency Department With Alcohol Use Problems and Suicidal Thoughts","EA-Avatar","Inclusion Criteria:\n\n* (1) emergency department admission for alcohol- or suicide-related reason since turning 18, OR treated for incidental suicide risk in the emergency department\n* (2) aged 18-29\n* (3) speak, read, and understand English\n* (4) binge drinking in the past month OR alcohol use problems (Alcohol Use Disorders Identification Test score \\> 5)\n* (5) active suicidal ideation in the past month\n* (6) owning and having access to a personal smartphone\n* (7) willingness to be randomized to an avatar guided intervention for alcohol use problems and suicidal thoughts OR a freely available suicide safety planning app\n* (8) for remote MyChart-based recruitment only, have MyChart activated\n\nExclusion Criteria:\n\n* (1) severe cognitive delay, active psychosis, or heavy intoxication that precludes research participation\n* (2) imminent safety risk and have been recently unsafe to themselves or others\n* (3) prisoner or are under arrest\n* (4) not interested or not willing to be randomized to receive the avatar-guided digital intervention or safety plan app\n* (5) under the care of a legal guardian","29 Years",{"count":19,"type":20},[23],"The goal of this clinical trial is to learn whether a novel digital avatar (virtual coach) support program can help emerging adults ages 18-29 who present to the emergency department with suicidal thoughts and alcohol misuse (EA-Avatar). The study also aims to learn whether people find the program easy to use and whether daily surveys and the study design are able to be completed by the majority of emerging adult participants.\n\nThe main questions this study aims to answer are:\n\n* Do participants use the digital program and find it helpful?\n* Is it possible for participants to complete daily surveys for twenty-eight days and follow-up surveys over twelve weeks?\n* Are there early signs that the program may help lower alcohol use and suicidal thoughts?\n\nResearchers will compare participants who receive the new digital avatar program plus supportive text messages to participants who receive a freely available suicide safety planning app to see if there are differences in use, engagement, and early signs of benefit.\n\nParticipants will:\n\n* Receive standard care from the emergency department\n* Be randomly put into one of two groups (EA-Avatar or a free suicide prevention app)\n* Depending on their group, use a new avatar-guided digital support program with text message reminders OR use a free suicide safety planning app\n* Complete surveys at the start of the study and again at four, eight, and twelve weeks\n* Complete short daily surveys for twenty-eight days",[556,26],"Binge Alcohol Consumption",[328,558,559,560,561,562],"binge drinking","emerging adults","feasibility","emergency department","digital health","2026-05-14",{"date":512,"type":36},{"date":566,"type":20},"2026-05-18",{"date":568,"type":20},"2026-08-31",{"name":570,"class":43},"University of Massachusetts, Worcester",2,{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":16,"minAge":141,"maxAge":142,"enrollmentInfo":580,"targetDuration":4,"studyType":21,"phases":581,"briefSummary":582,"conditions":583,"keywords":584,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":587,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":44},"100569958","integrated-suicide-supports-and-safety-planning-for-youth-100569958","NCT06701006","Integrated Suicide Supports and Safety Planning for Youth","Integrated Screening and Safety Planning (ISSP) for Adolescents With Suicidal Thoughts","ISSP","Youth Inclusion Criteria:\n\n* Age 13 -21 years, an Ask Suicide Questions (ASQ) screen score of 1-5 with active ideation (not solely a history of a prior attempt) but no current plan or intent, or patient-reported suicidal thoughts and behaviors during a clinical assessment in a medical setting who are judged by a clinician to be appropriate for conducting higher level assessment in that setting (including a BSSA and\u002For safety planning) in order to support care at home.\n* Parents\u002Fguardians: One \"parent\" per AYA will also be invited to participate.\n* HCPs: All HCPs in participating settings who may conduct assessments of SI and safety planning (physicians, nurse practitioners\u002Fphysician's assistants, social workers, mental health counselors, psychologists) will be invited to participate.\n* All subjects must have access to the internet and a computer or tablet device.\n\nYouth Exclusion Criteria:\n\n* Concurrently enrolled in an affiliated Suicide Care Research Center study, no phone access, or non-English speaking.",{"count":19,"type":20},[23],"The goal of this clinical trial is to evaluate an app to help keep teens and young adults with suicidal thoughts safe. The app includes a safety plan created by adolescents and healthcare providers, and videos to encourage supportive communication and skills for teens and young adults to stay safe. The main question it aims to answer is whether the use of an app can increase youth suicide-related coping for youth with suicidal ideation, parent\u002Fcaregiver suicide prevention self-efficacy, and healthcare provider self-efficacy in suicide management. Researchers will compare usual care to usual care with the app. Participants, including adolescents, caregivers, and healthcare providers, will use the ISSP app (if assigned to that group) and view video content and complete three online surveys.",[26,148],[332,585,220,586],"young adults","health services research",{"date":566,"type":36},{"date":589,"type":36},"2025-08-19",{"date":591,"type":20},"2026-11-01",{"name":593,"class":43},"University of Washington",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":16,"minAge":289,"maxAge":173,"enrollmentInfo":601,"targetDuration":4,"studyType":21,"phases":603,"briefSummary":604,"conditions":605,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":612,"leadSponsor":614,"locationsCount":44},"100622454","task-shifting-adapted-ipt-a-for-youth-suicide-prevention-100622454","NCT07383831","Task-Shifting Adapted IPT-A for Youth Suicide Prevention","Youth Mentor-Led Brief Interpersonal Psychotherapy for Youth Suicide Prevention","Inclusion Criteria:\n\n1. Parent consent\n2. Adolescent consent\n3. Enrolled in youth community centers\n4. Self-identified as Hispanic or Latine\n5. Between 12 and 17 years old.\n6. Scoring threshold for depression (4-9) as indicated in the PHQ-A.\n7. No current report of suicide ideation with plan or self-harming behaviors\n\nExclusion Criteria:\n\n1. Not consented to participate in the study\n2. Scoring 10 or higher in the PHQ-A, indicating depressive disorder\n3. Active suicide ideation (i.e., having thoughts of killing oneself, thinking about how in the past month).",{"count":602,"type":20},46,[23],"The goal of this randomized pragmatic clinical trial is to examine the feasibility, acceptability, and mechanisms of change of a brief adaptation of Interpersonal Psychotherapy for Adolescents (BIPT-A), adapted and task-shifted to lay providers (mentors, youth trusted adults) in youth community centers (YCCs) as an upstream approach to suicide.\n\nIt focuses on Hispanic adolescents ages 12-17 enrolled in these YCCs. The pragmatic clinical trial will evaluate the acceptability and feasibility of adapted IPT-A delivered by mentors in YCCs and whether adapted BIPT-A impacts mechanisms of change (depressive symptoms, belongingness, and burdensomeness or feeling like a burden to others).\n\nThe main questions to answer are:\n\n* Is adapted BIPT-A, when delivered by trained lay providers (youth mentors), feasible and acceptable in youth community centers?\n* Does adapted BIPT-A, delivered by lay providers, change key risk factors (i.e., key mechanisms: depressive symptoms, low belongingness, and perceived burdensomeness) associated with suicide ideation? The investigators will compare adolescents randomized to adapted BIPT-A (6 sessions) delivered by a trained youth mentor with those receiving usual services at the community center (one individual session focused on active listening).\n\nParticipants will:\n\n1. Be screened for subthreshold depression using the Patient Health Questionnaire Adolescent version (PHQ-A). Adolescent participants will be included if they score between 4 and 9 (mild depression). Participants with a PHQ-A score of 10 or higher (severe depression) will not be eligible and will be referred to a licensed mental health provider for appropriate care.\n2. Be randomized to adapted BIPT-A or usual care. Adolescent participants in the intervention arm will participate in 6 weekly, adapted BIPT-A sessions with a trained youth mentor. Intervention focuses on education, affect identification, and interpersonal skills.",[26,606,607],"Depressive Symptoms","Adolescent Mental Health","2026-05-08",{"date":610,"type":36},"2026-05-12",{"date":75,"type":20},{"date":613,"type":20},"2028-07-31",{"name":615,"class":43},"Boston College",{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":620,"acronym":4,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":16,"minAge":142,"maxAge":208,"enrollmentInfo":622,"targetDuration":4,"studyType":21,"phases":624,"briefSummary":625,"conditions":626,"keywords":630,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":44},"100499654","phase-2-the-impact-of-ampa-receptor-blockade-on-ketamines-anti-suicidal-effects-100499654","NCT05786066","The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects","Inclusion Criteria:\n\n* Current depression as indicated by a score greater than 17 on the full Hamilton Depression Rating Scale (HDRS-17) AND current major depressive episode as determined by structured clinical interview (SCID-5)\n* Current suicidal ideation as indicated by a score ≥ 2 on the HDRS-17 Item #3 (\"wishes to be dead (or any thoughts of possible death to self)\")\n* Anti-depressant resistant depressive symptoms, defined by a history of failure of one or more adequate anti-depressant trials\n* Participants will meet DSM-5 Criteria for MDD, PTSD or Bipolar Disorder as determined by the SCID-5\n* All participants given Ketamine must be engaged in mental health treatment outside of the research protocol. Those who are not receiving treatment with a mental health provider at the time of the phone screen may be referred for treatment and will have their admission to the protocol deferred until they are receiving treatment with a mental health provider for at least 4 weeks, at which time they may re-apply for admission to the protocol.\n* Individuals who are receiving pharmacotherapy for depression must have been receiving the current medication and dose for 4 weeks before randomization. Those who are not stable on their current medication and dose for 4 weeks at the time of the phone screen may have their admission to the protocol deferred until they are stable on their current psychopharmacotherapy. In addition, all individuals admitted to the protocol should have a plan to continue the current regime of pharmacotherapy for the duration of the trial.\n* Individuals who are receiving psychotherapy must have been in treatment for four weeks and should have a plan to continue the current regime of psychotherapy for the duration of the trial. Those who are not stable on their current regime of psychotherapy for 4 weeks at the time of the phone screen may have their admission to the protocol deferred until they are stable on their current regime of psychotherapy.\n* Willing to refrain from caffeine, drug, and alcohol use for one week prior to each Ketamine infusion\n* Females will be included if they are not pregnant or breastfeeding and agree to utilize a medically accepted birth control method (to include oral, injectable, or implant birth control, condom, diaphragm with spermicide, intrauterine device, tubal ligation, abstinence, or partner with vasectomy). Women who are surgically sterile or post-menopausal with cessation of menses for at least one year are not required to use birth control. If a woman should become pregnant during the study, she will be excluded from the trial.\n* Females will receive Ketamine during the follicular phase, i.e., in the first week after the start of the menstrual period, if at all possible. If a prospective participant typically has significant menstrual cramps during this entire follicular phase, she will be studied during another part of her cycle. She will be studied during the same part of her cycle for each scan, if possible.\n* Able to read and write English\n* Have at least a 12th grade education level or equivalent\n\nExclusion Criteria:\n\n* A score on the Columbia-Suicide Severity Rating Scale \\[43\\] in the \"intent\" or \"intent with plan\" categories within the last 3 months or judged by Dr. Krystal or Dr. Driesen to be at serious risk for suicide.\n* Psychiatric hospitalization in the past two months\n* Suicide attempt in the past two months\n* Neurological disorder excluding migraine headaches or mild head injury. More than mild head injury is indicated by the presence of any of the following:\n\n  * More than half hour unconsciousness after trauma\n  * More than one hour post-traumatic amnesia\n  * Concussive symptoms such as headache, memory problems, nausea\u002Fvomiting, irritability, ringing in the ears, dizziness, balance problems, difficulty concentrating or visual disturbances lasting more than one week after injury.\n  * Concussive symptoms as defined above in the first week after injury causing more than one day impairment in typical duties.\n  * Four or more concussive events of less severity than the above will also be grounds for exclusion. These events would include post-trauma symptoms such as the individual being dazed, seeing stars, unconscious for less than one half hour, or post-traumatic amnesia of less than an hour.\n* Current therapeutic treatment with Ketamine\n* Previous trial of Ketamine without therapeutic benefit\n* Current treatment with topiramate, memantine, or barbiturates within two weeks of randomization\n* Daytime use of benzodiazepines\n* Current treatment with monoamine oxidase inhibitors within 4 weeks of randomization\n* Treatment with a vagal nerve stimulator, ECT or deep brain stimulation within two weeks of randomization\n* Psychosis other than psychotic experiences congruent with depressed mood during a period of depression. Individuals experiencing psychosis during the current depressive episode will be excluded.\n* Other major medical disorder unless cleared by a study physician\n* History of violence unless cleared by Dr. Driesen or Dr. Krystal because of extenuating circumstances. For example, an individual whose violent behavior was always coupled with substance abuse and had obtained stable sobriety with no violent incidents or an individual who had received successful pharmacotherapy for impulse control difficulties may be included.\n* Individual meets criteria for a diagnosis of substance or alcohol use disorder within the three months prior to screening date. Individuals who meet criteria for mild alcohol use disorder within three months prior to screening date may be included in the study at investigator discretion. The diagnosis of mild alcohol use disorder shall be per DSM-5 and involve 2-3 symptoms. The PI's discretion will be based on the symptoms that are reported and the judged consistency and accuracy of the subjects' self-report.\n* A positive on screening urine drug test or, at the study physicians' discretion, on any drug screens given before the infusion visits.\n* A positive screening alcohol breathalyzer or alcohol saliva test or, at the study physicians' discretion, on any alcohol breathalyzer or alcohol saliva test given before the infusion visits.\n* A 12-lead ECG at screening has clinically significant abnormalities as determined by the physician reading the ECG.\n* Abnormality on clinical chemistry or hematology examination at the pre-study medical screening. Subjects with laboratory parameters outside the reference range for this age group will only be included if the study physician considers that such findings will not introduce additional risk factors.\n* History of positive HIV or Hepatitis B\n* Has received either prescribed or over-the-counter (OTC) centrally active medicine or herbal supplements within the week prior to the Ketamine infusion visit. Subjects who have taken OTC medication or herbal supplements may still be entered into the study, if, in the opinions of the Principal\u002FCo-Investigator, the medication received will not interfere with the study procedures or compromise safety.\n* Known sensitivity to Ketamine or heparin\n* Resting blood pressure lower than 85\u002F55 or higher than 140\u002F90, or resting heart rate lower than 45\u002Fmin or higher than 100\u002Fmin, unless cleared by study physician. If a subject meets these blood pressure entrance criteria, but is being treated for high blood pressure, the study team will check with the subject's primary care physician or treatment provider to confirm that the subject is stable and normotensive on their current treatment plan.\n* History of general intellectual disability\n* Donation of blood in excess of 500 mL within 56 days prior to dosing or similar loss of blood due to other causes.\n* Potential participants may be eliminated at the discretion of Dr. Krystal, Dr. Driesen, or the study physician.",{"count":623,"type":20},30,[56],"The purpose of this study is to test the hypothesis that the anti-depressant and anti-suicidal effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist Ketamine is critically dependent on stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid receptors (AMPAR).",[627,214,628,629,26],"Depressive Disorder","Bipolar Disorder","Post Traumatic Stress Disorder",[533,29],"2026-05-05",{"date":633,"type":36},"2026-05-06",{"date":635,"type":36},"2023-04-03",{"date":637,"type":20},"2033-03",{"name":639,"class":43},"Yale University",{"id":641,"slug":642,"hasResults":12,"nctId":643,"briefTitle":644,"officialTitle":645,"acronym":646,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":16,"minAge":648,"maxAge":649,"enrollmentInfo":650,"targetDuration":4,"studyType":21,"phases":651,"briefSummary":652,"conditions":653,"keywords":655,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":660,"completionDateStruct":661,"leadSponsor":663,"locationsCount":44},"100623370","youth-suicide-and-self-harm-intervention-clinical-and-biological-outcomes-study-100623370","NCT07395752","Youth Suicide and Self-Harm Intervention: Clinical and Biological Outcomes Study","Development and Biological Efficacy Validation of Youth Suicide and Self-Harm Intervention Program","SHIELD","Inclusion Criteria:\n\n1. General Criteria\n\n   * Aged between 15 and 30 years\n   * Obtained informed consent from a parent or legal guardian for participants under 19 years of age\n2. For the Self-Harm Group\n\n   * At least one incident of non-suicidal self-injury (NSSI) within the last 6 months\n   * Self-Harm Screening Inventory (SHSI) score of at least 1 (at least one \"Yes\" response)\n3. For the Suicide Attempt Group\n\n   * Suicide attempt within the last 6 months\n   * Depressive Symptom Inventory-Suicidality Subscale (DSI-SS) score of 3 or higher\n\nExclusion Criteria:\n\n1. Psychiatric and Developmental Conditions\n\n   * History of developmental disorders, including intellectual disability or autism spectrum disorder\n   * Diagnosis of schizophrenia or bipolar disorder\n   * Currently in an acute psychotic state\n2. Medical and Physical Conditions\n\n   * Presence of severe physical illness that interferes with daily life\n   * Presence of metallic substances in the body (e.g., cardiac pacemakers, artificial heart valves) that are incompatible with fMRI\n   * Diagnosis of claustrophobia\n   * Current Treatment and Intervention\n   * Currently receiving regular and active cognitive behavioral therapy (CBT)\n   * Initiation of pharmacological treatment within the last 2 months\n3. Communication and Consent\n\n   * Inability to communicate fluently in Korean\n   * Failure to obtain informed consent from a parent or legal guardian for participants under 19 years of age","15 Years","30 Years",{"count":88,"type":20},[23],"The goal of this clinical trial is to develop and evaluate youth-focused intervention programs for suicide and self-harm that are tailored to the psychological, developmental, and cultural characteristics of Korean adolescents and young adults. The study examines whether two structured, mindfulness-based intervention programs-one for middle and high school students and one for young adults-reduce suicidal ideation, self-harm behaviors, depressive symptoms, and emotion-regulation difficulties.\n\nThe study also aims to determine whether these clinical improvements are associated with biological changes, including alterations in resting-state functional brain activity (e.g., ALFF, ReHo, and functional connectivity) and social rhythm patterns.\n\nThe main questions this study seeks to answer are:\n\n* Does the youth suicide and self-harm intervention program reduce suicidal ideation and self-injurious thoughts\u002Fbehaviors?\n* Does the program improve mood, sleep, hopelessness, and emotion regulation?\n* Are improvements in clinical outcomes accompanied by changes in biological markers of suicide risk?\n* Researchers will compare the intervention program to usual care provided in hospitals, schools, and community mental health settings.\n\nParticipants will:\n\n* Participate in the structured suicide\u002Fself-harm intervention program or receive usual care.\n* Complete standardized assessments of mood, sleep, emotion regulation and suicide\u002Fself-harm risk.\n* Undergo biological assessments, including resting-state fMRI and rhythm-related measures, at baseline and follow-up.\n* Be followed for up to 12 weeks.",[26,654,93],"Self-Injurious Behavior",[413,362,415,656,657,185,446],"fMRI","Social rhythm","2026-05-04",{"date":608,"type":36},{"date":367,"type":36},{"date":662,"type":20},"2026-12-31",{"name":664,"class":43},"Ajou University School of Medicine",{"id":666,"slug":667,"hasResults":12,"nctId":668,"briefTitle":669,"officialTitle":670,"acronym":4,"eligibilityCriteria":671,"healthyVolunteers":207,"sex":16,"minAge":672,"maxAge":435,"enrollmentInfo":673,"targetDuration":4,"studyType":21,"phases":674,"briefSummary":675,"conditions":676,"keywords":678,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":679,"lastUpdatePostDateStruct":680,"startDateStruct":681,"completionDateStruct":683,"leadSponsor":685,"locationsCount":44},"100636620","neural-correlates-of-suicidal-behavior-in-youth-100636620","NCT07568054","Neural Correlates of Suicidal Behavior in Youth","Neural Correlates of Suicidal Behavior in Youth: a Pre and Post CAMS Therapy Neuroimaging Study","Inclusion Criteria:\n\n* Subjects must be 14-24 years old\n* Subjects must be:\n\n  * High Risk Subjects: Psychiatrically admitted due to a suicide attempt or history of 2 previous suicide attempts\n  * Medium Risk Subjects: Suicide ideation for the past year with no suicide attempt\n  * Minimal Risk Subjects: No previous history of suicidal ideation or behavior, not taking any psychiatric history or medication, and no family history of suicide\n* Subjects must have the ability to understand and the willingness to sign a written informed consent\u002Fassent document\n* Subjects must be English speaking\n\nExclusion Criteria:\n\n* Subjects with known history of Autism Spectrum Disorder; non-verbal patients\n* Subjects with moderate or severe intellectual disability (IQ less than 70 and those patients in special education classes full time)\n* Subjects with Schizophrenia or history of any type of psychosis including mood related psychosis and brief reactive psychosis\n* Within 6 months before initial screening, urine toxicology positive for phencyclidine, cocaine or amphetamines (subjects prescribed amphetamines for the management of ADHD will not be excluded)\n* Subjects with a history of moderate or severe substance or alcohol use per DSM-5 criteria in the past 6 months\n* Subjects who are currently pregnant or breastfeeding\n* Subjects in custody of Children's Services\n* Subjects with recent bone, tendon, spine or joint surgery\n* Subjects with recent metallic dental implants\n* Subjects weighing less than 30 kg or more than 200 kg","14 Years",{"count":19,"type":20},[23],"This study, titled \"Neural Correlates of Suicidal Behavior in Youth: a Pre and Post CAMS Therapy Neuroimaging Study,\" aims to better understand the brain mechanisms underlying suicidal thoughts and behaviors in adolescents and young adults (ages 14-24). Suicide is a leading cause of death in this population, and current clinical approaches often fail to accurately predict or prevent suicidal behavior. This study seeks to identify objective neurobiological markers associated with suicide risk and treatment response.\n\nParticipants will be divided into three groups: (1) high-risk individuals recently hospitalized following a suicide attempt, (2) medium-risk individuals with chronic suicidal ideation but no attempts, and (3) low-risk healthy controls. All participants will undergo advanced neuroimaging, including magnetoencephalography (MEG) and magnetic resonance imaging (MRI), along with comprehensive psychiatric assessments.\n\nThe study focuses on brain regions and networks implicated in suicidality, including the anterior cingulate cortex and salience network, as well as neurochemical markers such as glutamate. It also examines electrophysiological activity and functional connectivity patterns associated with suicidal thoughts and behaviors.\n\nHigh-risk participants will receive an evidence-based psychotherapy called the Collaborative Assessment and Management of Suicidality (CAMS). This therapeutic approach emphasizes collaboration between patient and clinician to identify and address the underlying drivers of suicidal thoughts, with a focus on increasing hope and reducing psychological distress. Neuroimaging and clinical assessments will be repeated after completion of CAMS to evaluate treatment-related changes.\n\nThe study's primary goals are to:\n\n* Identify neural and electrophysiological correlates of suicide risk.\n* Distinguish biological differences between individuals with suicidal ideation and those who have attempted suicide.\n* Determine how CAMS therapy affects brain function and neurochemistry.\n\nBy integrating clinical and neurobiological data, this research aims to improve understanding of suicidality, enhance risk prediction, and inform more effective, personalized interventions for at-risk youth.",[26,27,148,410,411,677],"Neurobiological",[362,415,416,413,151,411,417,534],"2026-04-29",{"date":631,"type":36},{"date":682,"type":20},"2026-04-13",{"date":684,"type":20},"2031-10-01",{"name":426,"class":43}]